“ADME Toxicology Testing Market Report is set to have rapid growth due increase un the drug discovery and development at global, regional and national level, influencing the industry trends in each of the sub-segments from 2019 to 2029”, says Visiongain Report
04 September 2019
Visiongain has launched a new pharma report ADME Toxicology Testing Market Forecast : By Technology (Cell Culture, OMICS Tech), By Application (Systemic Toxicity, Renal Toxicity), By Method, By Region, And Segment Forecasts
The global ADME Toxicology Testing market is poised for rapid growth between 2019 and 2029. An increasing number of drug molecules has failed in the final stages of clinical trials, resulting in precious time loss and investments in drug discovery and development. This has led to greater investments in the discovery of new technologies for toxicity testing, which is destined to strengthen the market over the next decade.
ADME toxicology tests are now conducted during the design and development of drugs to prevent any late-stage failure and to ensure a systematic assessment to prevent the potential loss of a molecule or investment. Most companies follow GLP and non-GLP testing procedures to meet regulatory standards.
With the growing need for new therapies for a number of conditions, it is likely that almost all technology segments will present profitable opportunities in the forecast period. The analysis of the processed and screened data is the most important step and must be managed precisely for the required results. Recent trends have seen the development of software and chemical libraries that can help establish the best standards and the communication of results.
The leading companies in the report include Accelrys Inc.; Agilent Technologies, Inc.; Albany Molecular Research Inc.; Beckman Coulter Inc.; Catalent Inc.; Charles River Laboratories International Inc.; AbbVie; Actelion Pharmaceuticals; Amgen; Biocon; BioMarin; Boehringer Ingelheim; Bristol-Myers Squibb; Cipla; and CymaBay Therapeutics.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Visiongain Publishes Automation in Biopharma Industry Market Report 2023-2033
The global Automation in Biopharma Industry market was valued at US$1,784.1 million in 2022 and is projected to grow at a CAGR of 5.7% during the forecast period 2023-2033.
20 March 2023
Visiongain Publishes eClinical Solutions Market Report 2023-2033
The global eClinical Solutions market was valued at US$8.03 billion in 2022 and is projected to grow at a CAGR of 13.09% during the forecast period 2023-2033.
17 March 2023
Visiongain Publishes Therapeutic Respiratory Devices Market Report 2023-2033
The global Therapeutic Respiratory Devices market was valued at US$59.49 billion in 2022 and is projected to grow at a CAGR of 8.02% during the forecast period 2023-2033.
15 March 2023
Visiongain Publishes Regenerative Medicine Market Report 2023-2033
The global Regenerative Medicine market was valued at US$ 50.37 billion in 2022 and is projected to grow at a CAGR of 18.40% during the forecast period 2023-2033.